FACTORS ASSOCIATED WITH BLEEDING EVENTS FROM LOW MOLECULAR WEIGHT HEPARIN USED IN ACUTE CORONARY SYNDROME PATIENTS
Not Applicable
Recruiting
- Conditions
- BLEEDING EVENTS FROM LOW MOLECULAR WEIGHT HEPARIN USED IN ACUTE CORONARY SYNDROME PATIENTSBleeding,Low molecular weight heparin,Acute coronary syndrome
- Registration Number
- TCTR20171225002
- Lead Sponsor
- Faculty of Pharmaceutical Sciences, Chulalongkorn University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 783
Inclusion Criteria
1. Age > 18 years.
2. Diagnosis of Acute coronary syndrome. (Unstable angina,non ST elevation myocardial infarction, ST elevation myocardial infarction)
3. Received at least one dose of low molecular weight heparin. (enoxaparin 1 mg/kg by subcutaneous injection)
Exclusion Criteria
1. Received thrombolytics or GP IIb/IIIa inhibitors.
2. Received unfractionated heparin after treatment with low molecular weight heparin.
3. Patients information from medical records not complete for follow up bleeding events.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bleeding events associated with low molecular weight heparin In 30 days first bleeding event after start low molecular weight heparin
- Secondary Outcome Measures
Name Time Method one none none